Name | Number of supported studies | Average coverage | |
---|---|---|---|
lung | 9 studies | 26% ± 13% | |
brain | 6 studies | 29% ± 10% | |
intestine | 6 studies | 20% ± 6% | |
peripheral blood | 5 studies | 29% ± 10% | |
liver | 4 studies | 26% ± 12% | |
pancreas | 3 studies | 28% ± 17% | |
placenta | 3 studies | 23% ± 3% | |
eye | 3 studies | 19% ± 3% | |
uterus | 3 studies | 30% ± 15% | |
breast | 3 studies | 17% ± 1% | |
bone marrow | 3 studies | 21% ± 4% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
bladder | 100% | 4873.81 | 21 / 21 | 100% | 76.20 | 504 / 504 |
esophagus | 100% | 5735.07 | 1445 / 1445 | 100% | 50.71 | 183 / 183 |
ovary | 100% | 3386.04 | 180 / 180 | 100% | 42.83 | 430 / 430 |
intestine | 100% | 4677.27 | 966 / 966 | 100% | 33.72 | 526 / 527 |
breast | 100% | 4556.46 | 459 / 459 | 100% | 45.65 | 1114 / 1118 |
prostate | 100% | 3848.85 | 245 / 245 | 100% | 54.94 | 500 / 502 |
stomach | 100% | 2822.53 | 358 / 359 | 100% | 33.45 | 285 / 286 |
lung | 99% | 3570.40 | 575 / 578 | 100% | 38.31 | 1153 / 1155 |
uterus | 100% | 3844.86 | 170 / 170 | 99% | 43.49 | 455 / 459 |
brain | 100% | 3837.42 | 2633 / 2642 | 99% | 37.47 | 701 / 705 |
thymus | 100% | 3300.57 | 652 / 653 | 99% | 32.31 | 600 / 605 |
skin | 100% | 10444.07 | 1809 / 1809 | 98% | 35.91 | 462 / 472 |
kidney | 100% | 4806.82 | 89 / 89 | 97% | 30.60 | 872 / 901 |
adrenal gland | 99% | 3193.71 | 256 / 258 | 88% | 22.27 | 202 / 230 |
pancreas | 82% | 1230.48 | 269 / 328 | 99% | 43.84 | 176 / 178 |
liver | 89% | 1377.86 | 202 / 226 | 91% | 19.51 | 371 / 406 |
adipose | 100% | 4784.04 | 1204 / 1204 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 100% | 29.83 | 29 / 29 |
spleen | 100% | 3260.16 | 241 / 241 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 100% | 37.89 | 1 / 1 |
blood vessel | 100% | 5209.83 | 1334 / 1335 | 0% | 0 | 0 / 0 |
muscle | 100% | 3656.59 | 802 / 803 | 0% | 0 | 0 / 0 |
peripheral blood | 99% | 4931.60 | 924 / 929 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 98% | 44.83 | 44 / 45 |
eye | 0% | 0 | 0 / 0 | 94% | 21.69 | 75 / 80 |
heart | 93% | 2622.15 | 800 / 861 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0090141 | Biological process | positive regulation of mitochondrial fission |
GO_0006897 | Biological process | endocytosis |
GO_0043547 | Biological process | positive regulation of GTPase activity |
GO_0055085 | Biological process | transmembrane transport |
GO_0051056 | Biological process | regulation of small GTPase mediated signal transduction |
GO_1990961 | Biological process | xenobiotic detoxification by transmembrane export across the plasma membrane |
GO_0032489 | Biological process | regulation of Cdc42 protein signal transduction |
GO_0006935 | Biological process | chemotaxis |
GO_0001934 | Biological process | positive regulation of protein phosphorylation |
GO_0043087 | Biological process | regulation of GTPase activity |
GO_0007264 | Biological process | small GTPase-mediated signal transduction |
GO_1900753 | Biological process | doxorubicin transport |
GO_0005886 | Cellular component | plasma membrane |
GO_0000922 | Cellular component | spindle pole |
GO_0016020 | Cellular component | membrane |
GO_0005739 | Cellular component | mitochondrion |
GO_0005654 | Cellular component | nucleoplasm |
GO_0016604 | Cellular component | nuclear body |
GO_0005829 | Cellular component | cytosol |
GO_0008559 | Molecular function | ABC-type xenobiotic transporter activity |
GO_0015431 | Molecular function | ABC-type glutathione S-conjugate transporter activity |
GO_0031267 | Molecular function | small GTPase binding |
GO_0005096 | Molecular function | GTPase activator activity |
GO_0042910 | Molecular function | xenobiotic transmembrane transporter activity |
GO_0005524 | Molecular function | ATP binding |
GO_0042626 | Molecular function | ATPase-coupled transmembrane transporter activity |
GO_0005515 | Molecular function | protein binding |
GO_0022857 | Molecular function | transmembrane transporter activity |
Gene name | RALBP1 |
Protein name | RALBP1 RalA binding protein 1 RalA-binding protein 1 (RalBP1) (76 kDa Ral-interacting protein) (Dinitrophenyl S-glutathione ATPase) (DNP-SG ATPase) (EC 7.6.2.2, EC 7.6.2.3) (Ral-interacting protein 1) |
Synonyms | RLIP RLIP1 RLIP76 |
Description | FUNCTION: Multifunctional protein that functions as a downstream effector of RALA and RALB . As a GTPase-activating protein/GAP can inactivate CDC42 and RAC1 by stimulating their GTPase activity . As part of the Ral signaling pathway, may also regulate ligand-dependent EGF and insulin receptors-mediated endocytosis . During mitosis, may act as a scaffold protein in the phosphorylation of EPSIN/EPN1 by the mitotic kinase cyclin B-CDK1, preventing endocytosis during that phase of the cell cycle . During mitosis, also controls mitochondrial fission as an effector of RALA . Recruited to mitochondrion by RALA, acts as a scaffold to foster the mitotic kinase cyclin B-CDK1-mediated phosphorylation and activation of DNM1L . .; FUNCTION: Could also function as a primary ATP-dependent active transporter for glutathione conjugates of electrophiles. May also actively catalyze the efflux of a wide range of substrates including xenobiotics like doxorubicin (DOX) contributing to cell multidrug resistance. . |
Accessions | ENST00000383432.8 E7ENF8 ENST00000458039.3 A0A2X0U2N0 ENST00000609094.2 ENST00000019317.8 Q15311 ENST00000585015.6 J3QLT3 A0A1W2PRI7 |